Literature DB >> 143343

In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin.

H Lazarus, V Raso, T S Samy.   

Abstract

Neocarzinostatin (NCS) is an acidic protein (molecular weight, 10,700) isolated from Streptomyces carzinostaticus that has antitumor activity both in model rodent systems and in humans. In vitro it inhibits the growth of a human lymphoblastic leukemic cell line (CCRF-CEM) at a very low concentration (the amount of drug that causes a 50% inhibition of growth compared to control cultures as extrapolated from a dose-response curve (ID50), 2.4 X 10(-9) M). We covalently coupled NCS to the N-hydroxysuccinimide ester of agarose and obtained a product that, by a variety of biochemical and immunological criteria, has been demonstrated to be devoid of any free or loosely bound NCS. Agarose-bound NCS, which is unable to enter cells because of its size, retains a significant amount of inhibitory activity (ID50, 6 to 15 X 10(-9) M) and is also capable of inhibiting tritiated deoxythymidine incorporation into CCRF-CEM cells. Since agarose-bound NCS cannot enter mammalian cells, the above findings indicate that NCS is able to exert its toxic effects by binding to or reacting with receptors on the cell membrane.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 143343

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Reinvestigation of the proteolytic activity of neocarzinostatin.

Authors:  B Heyd; G Lerat; E Adjadj; P Minard; M Desmadril
Journal:  J Bacteriol       Date:  2000-04       Impact factor: 3.490

2.  Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma.

Authors:  E Otsuji; T Takahashi; T Yamaguchi; N Yamaguchi; J Imanishi
Journal:  Gastroenterol Jpn       Date:  1990-04

3.  The role of monoclonal antibody A7 as a drug modifier in cancer therapy.

Authors:  K Kitamura; T Miyagaki; N Yamaoka; H Tsurumi; A Noguchi; T Yamaguchi; T Takahashi
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

4.  An uptake of fluorescein isothiocyanate labeled neocarzinostatin into the cancer and normal cells.

Authors:  S Sakamoto; H Maeda; J Ogata
Journal:  Experientia       Date:  1979-09-15

5.  Roles of chromophore and apo-protein in neocarzinostatin action.

Authors:  L S Kappen; M A Napier; I H Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.